Skip to main content
Top
Published in: Molecular Cancer 1/2024

Open Access 01-12-2024 | Artificial Intelligence | Correspondence

Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells

Authors: Natalia Malara, Maria Laura Coluccio, Fabiana Grillo, Teresa Ferrazzo, Nastassia C. Garo, Giuseppe Donato, Annamaria Lavecchia, Franco Fulciniti, Anna Sapino, Eliano Cascardi, Antonella Pellegrini, Prassede Foxi, Cesare Furlanello, Giovanni Negri, Guido Fadda, Arrigo Capitanio, Salvatore Pullano, Virginia M. Garo, Francesca Ferrazzo, Alarice Lowe, Angela Torsello, Patrizio Candeloro, Francesco Gentile

Published in: Molecular Cancer | Issue 1/2024

Login to get access

Abstract

Background

the problem in early diagnosis of sporadic cancer is understanding the individual’s risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models based on non-invasive screening tests. A tentative solution to the problem may be a cancer screening blood-based test able to discover those cell requirements triggering subclinical and clinical onset latency, at the stage when the cell disorder, i.e. atypical epithelial hyperplasia, is still in a subclinical stage of proliferative dysregulation.

Methods

a well-established procedure to identify proliferating circulating tumor cells was deployed to measure the cell proliferation of circulating non-haematological cells which may suggest tumor pathology. Moreover, the data collected were processed by a supervised machine learning model to make the prediction.

Results

the developed test combining circulating non-haematological cell proliferation data and artificial intelligence shows 98.8% of accuracy, 100% sensitivity, and 95% specificity.

Conclusion

this proof of concept study demonstrates that integration of innovative non invasive methods and predictive-models can be decisive in assessing the health status of an individual, and achieve cutting-edge results in cancer prevention and management.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Joseph L, Dieleman PD, Jackie Cao MS, Abby Chapin BA, Carina Chen MA, Zhiyin Li MS, Angela Liu C, Duber MD, MPH1,5, Abe C, Dunn, PhD6, Abraham D, Flaxman JL. Murray, MD, Dphil. US health care spending by payer and health condition, 1996–2016. JAMA. 2020; 323: 863–884. Joseph L, Dieleman PD, Jackie Cao MS, Abby Chapin BA, Carina Chen MA, Zhiyin Li MS, Angela Liu C, Duber MD, MPH1,5, Abe C, Dunn, PhD6, Abraham D, Flaxman JL. Murray, MD, Dphil. US health care spending by payer and health condition, 1996–2016. JAMA. 2020; 323: 863–884.
5.
go back to reference Malara N, Trunzo V, Foresta U et al. Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment. J Transl Med. 2016; 14, 133 (2016). https://doi.org/10.1186/s12967-016-0876-y. Malara N, Trunzo V, Foresta U et al. Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment. J Transl Med. 2016; 14, 133 (2016). https://​doi.​org/​10.​1186/​s12967-016-0876-y.
7.
go back to reference Yala A, Mikhael PG, Strand F, Lin G, Smith K, Wan Y, Lamb L, Hughes K, Lehman C, Barzilay R. Toward robust mammography-based models for breast cancer risk. Sci Transl Med. 2021;13(578):eaba4373.CrossRefPubMed Yala A, Mikhael PG, Strand F, Lin G, Smith K, Wan Y, Lamb L, Hughes K, Lehman C, Barzilay R. Toward robust mammography-based models for breast cancer risk. Sci Transl Med. 2021;13(578):eaba4373.CrossRefPubMed
11.
go back to reference Saxena K et al. Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival eBioMedicine, 46, 4–5. Saxena K et al. Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival eBioMedicine, 46, 4–5.
15.
go back to reference Onesto V, Villani M, Narducci R, Malara N, Imbrogno A, Allione, et al. Cortical-like mini-columns of neuronal cells on zinc oxide nanowire surfaces. Sci Rep. 2019;9(1):4021.CrossRefPubMedPubMedCentralADS Onesto V, Villani M, Narducci R, Malara N, Imbrogno A, Allione, et al. Cortical-like mini-columns of neuronal cells on zinc oxide nanowire surfaces. Sci Rep. 2019;9(1):4021.CrossRefPubMedPubMedCentralADS
Metadata
Title
Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells
Authors
Natalia Malara
Maria Laura Coluccio
Fabiana Grillo
Teresa Ferrazzo
Nastassia C. Garo
Giuseppe Donato
Annamaria Lavecchia
Franco Fulciniti
Anna Sapino
Eliano Cascardi
Antonella Pellegrini
Prassede Foxi
Cesare Furlanello
Giovanni Negri
Guido Fadda
Arrigo Capitanio
Salvatore Pullano
Virginia M. Garo
Francesca Ferrazzo
Alarice Lowe
Angela Torsello
Patrizio Candeloro
Francesco Gentile
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-024-01951-x

Other articles of this Issue 1/2024

Molecular Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine